Nanoparticles of VAV1 siRNA combined with LL37 peptide for the treatment of pancreatic cancer

Agbaria, Majd; Jbara-Agbaria, Doaa; Grad, Etty; David-Naim, Meital Ben; Aizik, Gil; Golomb, Gershon

doi:10.1016/j.jconrel.2023.01.084

Cited by 8 publications

(1 citation statement)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, nanoparticles containing LL-37 encapsulated with siRNA against VAV1 (a protein that is overexpressed in many tumors and associated with metastatic dissemination and poor prognosis) was highly effective at suppressing tumor development in a mouse model of pancreatic ductal adenocarcinoma, increasing survival while reducing VAV expression. LL-37 served a dual role as both a counter ion for the negatively charged siRNA and an anticancer peptide ( Agbaria et al, 2023 ). This approach emphasizes the potential of combining peptides with other chemotherapy drugs in nanomedicines to promote strong anticancer effects.…”

Section: Cathelicidins and Cancer Therapymentioning

confidence: 99%

Recent advances in the therapeutic potential of cathelicidins

Guerra,

Vieira,

Calazans

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

The alarming increase in antimicrobial resistance in the last decades has prompted the search for alternatives to control infectious diseases. Antimicrobial peptides (AMPs) represent a heterogeneous class of molecules with ample antibacterial, antiviral, and antifungal effects. They can be found in many organisms, including all classes of vertebrates, providing a valuable source of new antimicrobial agents. The unique properties of AMPs make it harder for microbes develop resistance, while their immunomodulatory properties and target diversity reinforce their translational use in multiple diseases, from autoimmune disorders to different types of cancer. The latest years have witnessed a vast number of studies evaluating the use of AMPs in therapy, with many progressing to clinical trials. The present review explores the recent developments in the medicinal properties of cathelicidins, a vast family of AMPs with potent antimicrobial and immunomodulatory effects. Cathelicidins from several organisms have been tested in disease models of viral and bacterial infections, inflammatory diseases, and tumors, with encouraging results. Combining nanomaterials with active, natural antimicrobial peptides, including LL-37 and synthetic analogs like ceragenins, leads to the creation of innovative nanoagents with significant clinical promise. However, there are still important limitations, such as the toxicity of many cathelicidins to healthy host cells and low stability in vivo. The recent advances in nanomaterials and synthetic biology may help overcome the current limitations, enabling the use of cathelicidins in future therapeutics. Furthermore, a better understanding of the mechanisms of cathelicidin action in vivo and their synergy with other host molecules will contribute to the development of safer, highly effective therapies.

show abstract

Section: Cathelicidins and Cancer Therapymentioning

confidence: 99%

Recent advances in the therapeutic potential of cathelicidins

Guerra,

Vieira,

Calazans

et al. 2024

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review

Lara,

Quiñonero,

Ortiz

et al. 2024

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Pancreatic cancer is one of the tumors with poor prognosis and low survival due to late diagnosis, high resistance, and very limited effective therapeutic options. Thus, new pharmacological treatments are necessary to improve the prognosis of patients. In this context, nanoparticles represent an efficient system for transporting and administering therapeutic molecules. Furthermore, siRNA can be used in cancer treatment to selectively inhibit the expression of any target gene. Therefore, nanoparticles associated with siRNA have been tested as a new therapeutic strategy to solve the pancreatic cancer treatment failure in the clinical setting. The current article presents a systematic revision of the literature of the last 10 years in which nanoparticles loading siRNA are used in pancreatic cancer. This research was carried out in three databases (PubMed, Scopus, and Web of Science) obtaining 164 articles from which 37 were selected. Our results show an overall view of the high effectiveness of this new therapy that combines nanoparticles with genetic therapy in pancreatic cancer suggesting that siRNA‐based medicines will likely open up a new therapeutic era in the treatment of this type of tumors.

show abstract